drugset / Trial / NCT05313009
Tarlox and Sotorasib in Patients With KRAS G12C Mutations
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a Phase IB dose expansion trial with safety lead-in evaluating the safety, clinical activity/efficacy of the combination of tarloxotinib and sotorasib in patients with KRAS G12C mutation who have progressed on any small molecule targeting KRAS G12C mutant Non-Small Cell lung cancer.
Timeline
- Start
- 2022-03-07
- Primary completion
- 2023-07-07
- Completion
- 2023-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sotorasib | Small molecule | 960 mg | Oral |
| Subject | Tarloxotinib | Unknown | 150 mg/m2 | Intravenous |